News

Filter by Category
Filter by Year

Nature Publishing Group: Synaffix to Participate in Webcast on Next-Gen Antibody Technologies

THE NETHERLANDS— November 26, 2015 — Dr. Floris van Delft, Founder and Chief Scientific Officer of Synaffix will participate in a BioPharma Dealmakers webcast, sponsored in part by Synaffix, featuring two companies innovating antibody technology.

The webcast, part of the BioPharma Dealmakers series, is scheduled for:

11:00 am ET / 5:00 pm CET on December 16

> Webcast registration link

The webcast will explore some of the technologies and companies ushering in the wave of next generation antibody technologies. Participants will learn about established approaches to improve antibody production and enhance the therapeutic index of ADCs — specifically proprietary approaches that have been shown to:

  • Generate high-quality antibodies in large quantities
  • Eliminate the formation of inclusion bodies in the antibody production
  • Result in safer and more effective ADCs by attaching drugs to the naturally-occurring glycan anchor point, present on all antibodies
  • Reduce ADC aggregation potential with a payload-enhancing linker technology

The webcast will include a round table discussion and a Q&A session to enable participants to contribute their own thoughts on this highly innovative field.

Dr. Floris van Delft, Ph.D., has been actively involved in the fields of click chemistry and protein conjugation technologies for many years. Other webcast participants include:

  • Phil Barish, Vice President of Operations and R&D of AbSci
  • Moderator : Gaspar Taroncher-Oldenburg, Ph.D. Dr. Taroncher-Oldenburg is an independent consultant and former managing editor of SciBX: Science-Business eXchange for Nature Publishing Group and the former scientific editor at Nature Biotechnology.

 

About the Webcast

BioPharma Dealmakers webcasts are dedicated to small and large companies looking for commercial partnerships. Read the quarterly BioPharma Dealmakers supplement in Nature Biotechnology and Nature Reviews Drug Discovery.

Contact

Anthony DeBoer

Director, Business Development

Synaffix BV

+31 620 773 194

Synaffix-FlorisvanDelft

Prof. Floris van Delft – CSO

Join Mailing List

Copyright Synaffix BV 2021. All Rights Reserved

Protein Conjugates

Bring your own and/or choose from the following categories. 

 

Just like our ADC technology, we can easily attach peptide and protein-based payloads to your antibody.

 

Early preclinical data available on request.

Bring Your Own

scFv / Fab
Cytokine

Immune Cell Recruiters

Anti-CD3

T cell recruitment
IL-15

NK cell recruitment

IL-15 Receptor Fusion

NK cell recruitment

HydraSpace™ Polar Spacer

Forming an integral part of every toxSYN™ linker-payload, HydraSpace™ bears a negative charge at physiological pH and improves:

  1. Therapeutic efficacy
  2. Tolerability
  3. PK
  4. Manufacturability
Key publication about HydraSpace

GlycoConnect™ design easily matches payload potency with the most appropriate drug-antibody ratio (DAR).

Key publications about GlycoConnect™

toxSYN™ Linker-Payloads

Choose from the following linker-payloads, attach to your antibody under a technology evaluation and go straight into ADC product development following positive POC.
toxSYN™
Linker-Payload
Mode-of-Action Payload
(Active Catabolite)
1. SYNtecan E™*Topoisomerase 1 inhibitor Camptothecin-based
2. SYNeamicin D™*DNA
damaging agent
Calicheamicin-based
3. SYNeamicin G™*
4. SYN-PNU™*Nemorubicin-based
5. SYNstatin E™Microtubule
inhibitors
Auristatin-based
6. SYNstatin F™
7. SYNtansine™ Maytansine-based

* Patent protection filed by Synaffix, beyond the claims of GlycoConnect™ and HydraSpace™

** N-6-aminohexanoyl-maytansine (Ahx-maytansine)